The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
PTC Therapeutics will need to carry out at least one further trial to demonstrate the effectiveness of its Duchenne Muscular Dystrophy therapy Translarna if it is to have a chance of bagging its approval in the US.